PaxMedica Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
PXMD Nasdaq 8731 https://www.paxmedica.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for PaxMedica Inc

PaxMedica's CEO and Malawi Health Official Discuss Urgent Medical Crisis in Bell2Bell Podcast - Apr 26th, 2024 12:30 pm
PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101 - Apr 23rd, 2024 12:30 pm
PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness - Apr 16th, 2024 8:30 pm
PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission - Apr 11th, 2024 8:30 pm
PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments - Mar 13th, 2024 12:20 pm
IBN Highlights PaxMedica's Video Release on Transformative ASD Study - Jan 18th, 2024 1:30 pm
PaxMedica on Promising Path to Address Unmet ASD Needs - Jan 17th, 2024 1:30 pm
PaxMedica Files 8-K Following Nasdaq Compliance Achievement - Dec 22nd, 2023 7:00 pm
PaxMedica CEO Howard Weisman Sheds Light on Achievements for ASD Therapy Pipeline - Dec 19th, 2023 2:30 pm
PaxMedica Inc. Covered in H.C. Wainwright & Co. Research Report - Dec 12th, 2023 2:00 pm
PaxMedica CEO Featured in Just-Released Fireside Chat Video - Dec 8th, 2023 1:30 pm
PaxMedica Closes Public Offering of Approximately $7M, Continues Pursuing ASD Pipeline - Dec 7th, 2023 2:00 pm
PaxMedica Releases Fireside Chat Video with CEO Howard Weisman - Dec 6th, 2023 1:00 pm
PaxMedica Closes on Public Offering Reaching Estimated $7M - Dec 1st, 2023 6:30 pm
PaxMedica Announces Closing of $7.0 Million Public Offering - Nov 22nd, 2023 9:10 pm
PaxMedica Announces Pricing of $7M Public Offering - Nov 22nd, 2023 1:30 pm
PaxMedica News of FDA Type-B Meeting Shared in Audio Broadcast - Nov 21st, 2023 2:00 pm
PaxMedica Announces Pricing of $7.0 Million Public Offering - Nov 20th, 2023 2:15 pm
PaxMedica Releases Q3 2023 Financial Report, Corporate Update - Nov 17th, 2023 8:00 pm
PaxMedica Inc. Featured in Syndicated Broadcast Highlighting FDA Type-B Meeting to Review PAX-101 Pivotal Trial Data - Nov 17th, 2023 1:00 pm